MEMORIAL SLOAN-KETTERING CANCER CENTER 
1 2 7 3 YORK AVENUE. NEW YORK. NEW YORK 10021 
September 18, 1978 
Dr. Donald S. Fredrickson 
National Institutes of Health 
Bethesda, Maryland 20014 
Dear Dr. Fredrickson: 
I am writing on a matter of great importance to science. Work has been 
held up in recombinant DNA studies because of guidelines and uncertainties 
they have generated. 
In the further development of regulations with respect to recombinant DNA 
research, I urge that all steps necessary be taken to retain the development 
of national guidelines and possible future modifications of them under the 
aegis of NIH. The guidelines should not be imposed by a less knowledgeable 
group no matter how good their intentions might be. NIH is in the best 
position to establish appropriate guidelines for research in that area because 
of its experience, the expertise readily available to it and the probability it 
is, and will be, funding most of the research on recombinant DNA. 
Although I am not personally engaged in such research ,1 believe strongly that 
following the course recommended above will be best for that field and for 
science in general. 
C. Chester Stock, Ph.D. 
Vice President and Associate Director 
for Administrative and Academic Affairs 
[A-171] 
MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES 
SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH 
SLOAN-KETTERING DIVISION. GRADUATE SCHOOL OF MEDICAL SCIENCES. CORNELL UNIVERSITY 
